TROPICAL DISEASE RESEARCH UNITS
RELEASE DATE: April 2, 2003
RFA: AI-03-018
National Institute of Allergy and Infectious Diseases (NIAID)
(http://www.niaid.nih.gov)
CATALOGUE OF FEDERAL DOMESTIC ASSISTANCE NUMBERS:
No. 93.855, Immunology, Allergy, and Transplantation Research
No. 93.856, Microbiology and Infectious Diseases Research
LETTER OF INTENT RECEIPT DATE: July 19, 2003
APPLICATION RECEIPT DATE: August 19, 2003
THIS RFA CONTAINS THE FOLLOWING INFORMATION
o Purpose of this RFA
o Research Objectives
o Mechanism(s) of Support
o Funds Available
o Eligible Institutions
o Individuals Eligible to Become Principal Investigators
o Special Requirements
o Where to Send Inquiries
o Letter of Intent
o Submitting an Application
o Peer Review Process
o Review Criteria
o Receipt and Review Schedule
o Award Criteria
o Required Federal Citations
PURPOSE OF THIS RFA
The National Institute of Allergy and Infectious Diseases (NIAID), National
Institutes of Health (NIH), invites applications for program project (P01)
grants to conduct multidisciplinary research leading to the development and
evaluation of new strategies to prevent and control diseases caused by
protozoan and helminth parasites. Programs will focus on one of the following
areas: (1) therapeutics -- discovery and validation of drug targets and
development of new chemotherapeutic agents for treating and preventing
parasitic infections; or (2) vector control -- development of new approaches
for interruption of the parasite life cycle at the level of the invertebrate
(vector) host.
RESEARCH OBJECTIVES
Background
Parasitic diseases continue to represent tremendous public health problems,
especially for people living in the tropics where parasitic infections are
responsible for deaths and impaired growth and development among children as
well as for debilitating, chronic diseases among adults. Parasitic infections
have been recognized with increasing frequency as responsible for diseases in
the United States and other industrialized countries. Of special interest to
clinicians and public health workers in developed nations is the occurrence of
severe parasitic disease in individuals who acquired their infection
congenitally or as a result of immunosuppression.
Prevention and treatment of parasitic diseases remain problematic. Many of
the currently available drugs exhibit either excessive toxicity and/or
inadequate efficacy. Several previously useful compounds are no longer
effective due to the spread of drug resistant parasite variants. Licensed
vaccines do not exist for any human parasitic infection. Erosion of public
health vector control programs, appearance of insecticide resistance among
vector populations and environmental changes, notably those associated with
land and water management practices, has contributed to the emergence or re-
emergence of parasitic diseases.
In response to growing concerns about the use of biological agents in acts of
terrorism, NIAID has developed a strategic plan for research on biodefense and
emerging infectious diseases
(http://www.niaid.nih.gov/biodefense/research/strategic.pdf). As a focus of
this strategic plan, the NIAID has identified a number of priority organisms,
including several food and water borne protozoan pathogens
(http://www.niaid.nih.gov/biodefense/bandc_priority.htm). Translational
research leading to the development of new therapeutics to treat diseases
caused by these pathogens is encouraged.
Current parasitology research supported by the DMID, NIAID, is largely
conducted under investigator initiated research project grants focusing on the
molecular and cellular biology, immunology, and biochemistry of the medically
important protozoa and helminths as well as on the biology of invertebrate
vectors. The Institute also supports several special programs for studies on
parasitic and other tropical diseases. Research reagents in support of
schistosomiasis, filariasis and malaria research are available through
repository contracts funded by NIAID
(http://www.niaid.nih.gov/reposit/default.htm). The International Centers for
Tropical Disease Research (ICTDR) network serves to coordinate many of the
Institute's activities in the area of tropical infectious diseases. Within
the ICTDR network, studies in areas endemic for tropical parasitic diseases
are funded through its International Collaboration in Infectious Disease
Research (ICIDR) and Tropical Medicine Research Center (TMRC) programs.
Available resources in endemic areas supported by the ICIDR and TMRC programs
may provide opportunities for field testing of new intervention strategies as
they arise. In addition, NIAID is developing clinical trial sites in endemic
areas for evaluation of malaria vaccines or therapies.
This RFA represents a continuation of another major component of NIAID's ICTDR
network, the Tropical Disease Research Units (TDRUs). This program was
initiated in 1980 and originally designed to stimulate advanced biomedical
research on the five parasitic diseases that form the basis of the World
Health Organization's Special Programme for Research and Training in Tropical
Diseases (WHO/TDR) -- filariasis, leishmaniasis, malaria, schistosomiasis and
trypanosomiasis. Since the inception of the TDRU program, much has been
learned about the biology of these and other parasites as a result of the
dramatic advances in molecular and cellular biology and in immunology. Recent
advances in our understanding of the basic biology of parasites and of
invertebrate vectors and of host-parasite interactions have created unique
opportunities for discovering and evaluating new means of controlling the
mortality and morbidity associated with parasitic infections. In 1995,
recognizing that substantial advances have been made in the understanding of
many parasitic diseases of significant global public health impact, the NIAID
expanded the scope of the TDRU program to encompass all medically important
human parasitic diseases.
Under the current renewal, TDRUs will be expected to provide focused concerted
efforts in the development and preclinical and pre-field testing of new
intervention strategies for parasitic diseases. Components of the TDRU
program may have the opportunity to work with other members of the ICTDR
network to move promising therapeutic or vector control strategies toward
clinical or field trials. Opportunities for moving candidate therapeutics or
vector control methods into clinical and field-testing are also available
through other mechanisms.
Research Objectives and Scope
NIAID wishes to support multidisciplinary, state-of-the-art biomedical
research units focused on preclinical and pre-field) testing of new
intervention strategies to control protozoal and helminthic infections.
For the purpose of this RFA, intervention strategies to be considered are: i)
therapeutic agents to prevent and/or treat infection; and ii) methods to
control invertebrate vectors. The entire program project grant (see
definition under 'MECHANISM OF SUPPORT'), must address the development of one
of these intervention strategies. The program project must also focus on a
single parasitic infection or a single related target common to several
parasitic organisms or vectors. Studies on human pathogens are preferred but
studies on animal pathogens that are recognized to provide relevant models of
human disease will also be acceptable.
The entire program project should be designed to address the common goal in a
cohesive manner. Responsive programs would be those in which each project
provides information necessary for further development of the single
intervention strategy chosen as the overall program objective and/or
evaluation of its utility in an appropriate in vitro or in vivo system. Each
program project application must clearly define the coordinating structure to
be used to ensure integration and information exchange among the different
projects of the program in pursuit of this single goal.
Therapeutics:
NIAID wishes to support research units that consist of focused, coordinated
projects with a common preclinical development objective. Of significant
interest are units with methods and /or test systems for accelerated
evaluation/selection of preclinical candidate therapeutic compounds. Proposed
units with crosscutting, complementary disciplines that are designed to more
rapidly facilitate selection of preclinical chemotherapy candidates are of
special interest. Efforts to facilitate high throughput screening (HTS) of
chemical candidates and lead selection and optimization may include combined
areas of chemical synthesis, medicinal chemistry and proteomic target
expression. Another combined effort may be use of appropriate test systems
for integration of preclinical phamacokinetics, efficacy pharmacodynamics and
metabolism of candidate compounds. Areas of research relevant to this program
include, but are not restricted to, studies designed to:
o Identify and characterize novel potential targets of chemotherapeutic
agents for medically relevant protozoa or helminth pathogens; of special
interest are targets that can be validated and applied to high throughput
screening methodologies for lead compound discovery;
o Elucidate mechanisms of resistance to antiparasitic agents; develop
methods or strategies to overcome such resistance;
o Identify lead compounds utilizing molecular modeling and/or library
screening methods;
o Develop methods or systems of reiterative design, chemical synthesis and
in vitro or animal testing for the selection of lead compounds; and
o Develop methods and/or systems for preclinical evaluation of candidate
therapeutics with a goal of expeditiously moving drug candidates into phase I
clinical trials (http://www.fda.gov/cder/regulatory/default.htm).
Vector control:
NIAID wishes to support research units focused on development and testing of
novel, environmentally sound intervention strategies for vector-borne
infectious diseases. This research should be translational in nature, and
should focus on one or more specific public health vector control
interventions. Ideally, the vector control research supported under the TDRU
program should be just short of wide scale field trials, and the results of
the research funded under the TDRU program will be quickly testable in large-
scale field trials in endemic areas. Applicants responding to this area of the
announcement should include a description of the intervention(s), its/their
stage of development, and justification for its/their being ready to move to
this pre-field or limited field-testing stage. Areas of research relevant to
this program include, but are not restricted to studies designed to:
o Assess attractant-baited traps as point source removal strategies,
especially for vectors like Culex (oviposition traps) or Anopheles (bednet
traps);
o Adapt IPM strategies for community-specific vector-control; and
o Develop biological control agents targeted to individual vector species,
e.g. densoviruses.
Validation:
Each application, whether targeted to therapeutics or vector control, must
provide an experimental plan that details the methods that will be used to
validate the utility of the chosen approach. The experimental plans must
indicate relevant validation strategies and major decision milestones.
Examples of validation strategies include:
o Use of site-directed mutagenesis, gene knockouts, testing of specific
inhibitors, antisense technology or RNAi to establish the essential nature of
a drug target;
o Examination of the inhibition of infection, parasite function or of
documented correlates of pathology in in vitro or animal model systems in
programs seeking to develop therapeutic agents; and
o Assessment of the effectiveness of the vector control product or
strategy in reducing transmission of the parasite to humans, through its
impact on vector abundance, density, longevity etc.
MECHANISM OF SUPPORT
This RFA will use the NIH program project (P01) award mechanism. As an
applicant you will be solely responsible for planning, directing, and
executing the proposed project. This type of award supports broadly based
multidisciplinary research programs that have a well-defined central research
focus or objective. An important feature is that the interrelationships among
the individual scientifically meritorious projects will result in a greater
contribution to the overall program goals than if each project was pursued
individually. The program project grant consists of a minimum of three
interrelated individual research projects that contribute to the program
objective. The award also can provide support for certain common resources
termed cores. Such resources should be utilized by two or more projects within
the award.
This RFA is a one-time solicitation. Future unsolicited, competing-
continuation applications based on this project will compete with all
investigator-initiated applications and will be reviewed according to the
customary peer review procedures.
FUNDS AVAILABLE
NIAID intends to commit approximately $2.4M in FY 2004 to fund 3 to 5 new
and/or competitive continuation grants in response to this RFA. An applicant
may request a project period of up to five years and a budget for total costs
of up to $800K per year. Because the nature and scope of the proposed research
will vary from application to application, it is anticipated that the size and
duration of each award will also vary. Although the financial plans of NIAID
provide support for this program, awards pursuant to this RFA are contingent
upon the availability of funds and the receipt of a sufficient number of
meritorious applications.
ELIGIBLE INSTITUTIONS
You may submit (an) application(s) if your institution has any of the
following characteristics:
o For-profit or non-profit organizations
o Public or private institutions, such as universities, colleges, hospitals,
and laboratories
o Units of State and local governments
o Eligible agencies of the Federal government
o Domestic
o Faith-based or community-based organizations
Foreign organizations are not eligible to apply; however, collaboration(s)
with investigators at foreign sites are encouraged.
INDIVIDUALS ELIGIBLE TO BECOME PRINCIPAL INVESTIGATORS
Any individual with the skills, knowledge, and resources necessary to carry
out the proposed research is invited to work with their institution to develop
an application for support. Individuals from underrepresented racial and
ethnic groups as well as individuals with disabilities are always encouraged
to apply for NIH programs.
SPECIAL REQUIREMENTS
When clinical studies are a component of the research proposed, NIAID policy
requires that studies be monitored commensurate with the degree of potential
risk to study subjects and the complexity of the study. AN UPDATED NIAID
policy was published in the NIH Guide on July 8, 2002 and is available at:
https://grants.nih.gov/grants/guide/notice-files/NOT-AI-02-032.html. The full
policy, including terms and conditions of award, is available at:
http://www.niaid.nih.gov/ncn/pdf/clinterm.pdf.
Development of vector control products that are intended for use in the
environment will eventually require review and approval of appropriate
regulatory agencies (in the U.S. the Environmental Protection Agency). While
any field application proposed must have the necessary regulatory approvals,
even earlier development phases should be undertaken with this requirement in
mind. Applicants are encouraged to discuss their plans with NIAID staff prior
to submission and to be explicit within the application itself about the
regulatory approval process.
Institutions receiving TDRU awards are considered as Centers in the NIAID
ICTDR network, and TDRU program directors are designated as Center Directors
in this network. A further description of the network available on the NIAID
Website at http://www.niaid.nih.gov/ictdr. The application should budget
appropriate funds to allow the TDRU program director to attend the annual
meeting of the network that is generally held in Bethesda in the Spring.
Attendance of other key personnel is encouraged.
WHERE TO SEND INQUIRIES
We encourage inquiries concerning this RFA and welcome the opportunity to
answer questions from potential applicants. Inquiries fall into three areas:
scientific/research; peer review; and financial or grants management issues:
o Direct your questions about scientific/research issues related to
THERAPEUTICS to:
Michael Gottlieb, Ph.D.
Division of Microbiology and Infectious Diseases
National Institute of Allergy and Infectious Diseases
Room 5099, MSC-6603
6610 Rockledge Drive
Bethesda, MD 20892-6603
[for express mail use Bethesda, MD 20817]
Telephone: (301) 496-2544
FAX: (301) 402-0659
Email: mgottlieb@niaid.nih.gov
o Direct your questions about scientific/research issues related to VECTOR
CONTROL to:
Kathryn Aultman Ph.D.
Division of Microbiology and Infectious Diseases
National Institute of Allergy and Infectious Diseases
Room 5097, MSC-6603
6610 Rockledge Drive
Bethesda, MD 20892-6603
[for express mail use Bethesda, MD 20817]
Telephone: (301) 435-2854
FAX: (301) 402-0659
Email: ka6z@nih.gov
o Direct your questions about peer review issues to:
Madelon C. Halula, Ph.D.
Division of Extramural Activities
National Institute of Allergy and Infectious Diseases
Room 2150, MSC-7616
6700-B Rockledge Drive
Bethesda, MD 20892-7616
Telephone: (301)402-2636
FAX: (301) 402-2638
Email: mh30x@nih.gov
o Direct your questions about financial or grants management issues o:
Mollie Shea
Division of Extramural Activities
National Institute of Allergy and Infectious Diseases
Room 2234, MSC-7614
6700-B Rockledge Drive
Bethesda, MD 20892-7614
[for express mail use Bethesda, MD 20817]
Telephone: (301) 402-6576
FAX: (301) 480 3780
Email: ms256g@nih.gov
LETTER OF INTENT
Prospective applicants are asked to submit a letter of intent that includes
the following information:
o Descriptive title of the proposed research
o Name, address, and telephone number of the Principal Investigator
o Names of other key personnel
o Participating institutions
o Number and title of this RFA
Although a letter of intent is not required, is not binding, and does not
enter into the review of a subsequent application, the information that it
contains allows IC staff to estimate the potential review workload and plan
the review.
The letter of intent is to be sent by the date listed at the beginning of this
document. The letter of intent should be sent to:
Madelon C. Halula, Ph.D.
Division of Extramural Activities
National Institute of Allergy and Infectious Diseases
Room 2150, MSC-7616
6700-B Rockledge Drive
Bethesda, MD 20892-7616
Telephone: (301)402-2636
FAX: (301) 402-2638
Email: mh30x@nih.gov
SUBMITTING AN APPLICATION
Applicants for P01 grants must follow special application guidelines in the
NIAID Brochure entitled INSTRUCTIONS FOR APPLICATIONS FOR MULTI-PROJECT
AWARDS; this brochure is available via the WWW at:
http://www.niaid.nih.gov/ncn/grants/multibron.htm.
Applications must be prepared using the PHS 398 research grant application
instructions and forms (rev. 5/2001). The PHS 398 is available at
https://grants.nih.gov/grants/funding/phs398/phs398.html in an interactive
format. For further assistance contact Grants Info, Telephone (301) 710-0267,
Email: GrantsInfo@nih.gov.
USING THE RFA LABEL: The RFA label available in the PHS 398 (rev. 5/2001)
application form must be affixed to the bottom of the face page of the
application. Type the RFA number on the label. Failure to use this label could
result in delayed processing of the application such that it may not reach the
review committee in time for review. In addition, the RFA title and number
must be typed on line 2 of the face page of the application form and the YES
box must be marked. The RFA label is also available at:
https://grants.nih.gov/grants/funding/phs398/label-bk.pdf.
SENDING AN APPLICATION TO THE NIH: Submit a signed, typewritten original of
the application, including the Checklist, and three signed, photocopies, in
one package to:
Center For Scientific Review
National Institutes Of Health
6701 Rockledge Drive, Room 1040, MSC 7710
Bethesda, MD 20892-7710
Bethesda, MD 20817 (for express/courier service)
At the time of submission, two additional exact copies of the grant
application and all five sets of any appendix material must be sent to:
Madelon C. Halula, Ph.D.
Division of Extramural Activities
National Institute of Allergy and Infectious Diseases
Room 2150, MSC-7616
6700-B Rockledge Drive
Bethesda, MD 20892-7616
Bethesda, MD 20817 (for express mail or courier service)
Applications must be received by August 19, 2003. Applications that are not
received as a single package on the receipt date or that do not conform to the
instructions contained in PHS 398 (rev. 5/01) Application Kit (as modified in,
and superseded by, the NIAID BROCHURE ENTITLED "INSTRUCTIONS FOR APPLICATIONS
FOR MULTI-PROJECT AWARDS"), will be judged non-responsive and will be returned
to the applicant.
APPLICATION PROCESSING: Applications must be received by the application
receipt date listed in the heading of this RFA. If an application is received
after that date, it will be returned to the applicant without review.
The Center for Scientific Review (CSR) will not accept any application in
response to this RFA that is essentially the same as one currently pending
initial review, unless the applicant withdraws the pending application.
However, when a previously unfunded application, originally submitted as an
investigator-initiated application, is to be submitted in response to an RFA,
it is to be prepared as a NEW application. That is the application for the
RFA must not include an Introduction describing the changes and improvements
made, and the text must not be marked to indicate the changes. While the
investigator may still benefit from the previous review, the RFA application
is not to state explicitly how.
Concurrent submission of an R01 and a Component Project of a Multi-project
Application: Current NIH policy permits a component research project of a
multi-project grant application to be concurrently submitted as a traditional
individual research project (R01) application. If, following review, both the
multi-project application and the R01 application are found to be in the
fundable range, the investigator must relinquish the R01 and will not have the
option to withdraw from the multi-project grant. This is an NIH policy
intended to preserve the scientific integrity of a multi-project grant, which
may be seriously compromised if a strong component project(s) is removed from
the program. Investigators wishing to participate in a multi-project grant
must be aware of this policy before making a commitment to the Principal
Investigator and awarding institution.
Although there is no immediate acknowledgement of the receipt of an
application, applicants are generally notified of the review and funding
assignment within 8 weeks.
PEER REVIEW PROCESS
Upon receipt, applications will be reviewed for completeness by the CSR and
responsiveness by NIAID.
Incomplete and/or non-responsive applications will be returned to the
applicant without further consideration.
Applications that are complete and responsive to the RFA will be evaluated for
scientific and technical merit by an appropriate peer review group convened by
NIAID in accordance with the review criteria stated below. As part of the
initial merit review, all applications will:
o Receive a written critique
o Undergo a selection process in which only those applications deemed to have
the highest scientific merit, generally the top half of applications under
review, will be discussed and assigned a priority score
o Receive a second level review by the National Advisory Allergy and
Infectious Diseases Council
REVIEW CRITERIA
The general review criteria for P01 grant applications are presented in the
NIAID brochure entitled "INSTRUCTIONS FOR APPLICATIONS FOR MULTI-PROJECT
AWARDS" at http://www.niaid.nih.gov/ncn/grants/multibron.htm.
ADDITIONAL REVIEW CRITERIA: In addition, the following review criteria items
will be considered in the determination of scientific merit and the priority
score:
PROTECTION OF HUMAN SUBJECTS FROM RESEARCH RISK: The involvement of human
subjects and protections from research risk relating to their participation in
the proposed research will be assessed. (See criteria included in the section
on Federal Citations, below)
INCLUSION OF WOMEN, MINORITIES AND CHILDREN IN RESEARCH: The adequacy of plans
to include subjects from both genders, all racial and ethnic groups (and
subgroups), and children as appropriate for the scientific goals of the
research. Plans for the recruitment and retention of subjects will also be
evaluated. (See Inclusion Criteria in the sections on Federal Citations,
below).
CARE AND USE OF VERTEBRATE ANIMALS IN RESEARCH: If vertebrate animals are to
be used in the project, the five items described under Section f of the PHS
398 research grant application instructions (rev. 5/2001) will be assessed.
ADDITIONAL CONSIDERATIONS
DATA SHARING: The adequacy of the proposed plan to share data.
BUDGET: The reasonableness of the proposed budget and the requested period of
support in relation to the proposed research.
RECEIPT AND REVIEW SCHEDULE
Letter of Intent Receipt Date: July 18, 2003
Application Receipt Date: August 19, 2003
Scientific Peer Review Date: December, 2003
Advisory Council Review: February, 2004
Earliest Anticipated Start Date: April, 2004
AWARD CRITERIA
Award criteria that will be used to make award decisions include:
o Scientific merit of the proposed project as determined by peer review
o Availability of funds
o Programmatic priorities.
REQUIRED FEDERAL CITATIONS
HUMAN SUBJECTS PROTECTION: Federal regulations (45CFR46) require that
applications and proposals involving human subjects must be evaluated with
reference to the risks to the subjects, the adequacy of protection against
these risks, the potential benefits of the research to the subjects and
others, and the importance of the knowledge gained or to be gained.
INCLUSION OF WOMEN AND MINORITIES IN CLINICAL RESEARCH: It is the policy of
the NIH that women and members of minority groups and their sub-populations
must be included in all NIH-supported clinical research projects unless a
clear and compelling justification is provided indicating that inclusion is
inappropriate with respect to the health of the subjects or the purpose of the
research. This policy results from the NIH Revitalization Act of 1993 (Section
492B of Public Law 103-43).
All investigators proposing clinical research should read the AMENDMENT "NIH
Guidelines for Inclusion of Women and Minorities as Subjects in Clinical
Research - Amended, October, 2001," published in the NIH Guide for Grants and
Contracts on October 9, 2001 (https://grants.nih.gov/grants/guide/notice-
files/NOT-OD-02-001.html); a complete copy of the updated Guidelines are
available at https://grants.nih.gov/grants/funding/women_min/guidelines_amended_
10_2001.htm. The amended policy incorporates: the use of an NIH definition
of clinical research; updated racial and ethnic categories in compliance with
the new OMB standards; clarification of language governing NIH-defined Phase
III clinical trials consistent with the new PHS Form 398; and updated roles and
responsibilities of NIH staff and the extramural community. The policy
continues to require for all NIH-defined Phase III clinical trials that: a)
all applications or proposals and/or protocols must provide a description of
plans to conduct analyses, as appropriate, to address differences by
sex/gender and/or racial/ethnic groups, including subgroups if applicable; and
b) investigators must report annual accrual and progress in conducting
analyses, as appropriate, by sex/gender and/or racial/ethnic group
differences.
INCLUSION OF CHILDREN AS PARTICIPANTS IN RESEARCH INVOLVING HUMAN SUBJECTS:
The NIH maintains a policy that children (i.e., individuals under the age of
21) must be included in all human subjects research, conducted or supported by
the NIH, unless there are scientific and ethical reasons not to include them.
This policy applies to all initial (Type 1) applications submitted for receipt
dates after October 1, 1998.
All investigators proposing research involving human subjects should read the
"NIH Policy and Guidelines" on the inclusion of children as participants in
research involving human subjects that is available at
https://grants.nih.gov/grants/funding/children/children.htm.
REQUIRED EDUCATION ON THE PROTECTION OF HUMAN SUBJECT PARTICIPANTS: NIH policy
requires education on the protection of human subject participants for all
investigators submitting NIH proposals for research involving human subjects.
This policy announcement is in the NIH Guide for Grants and Contracts
Announcement, dated June 5, 2000, at
https://grants.nih.gov/grants/guide/notice-files/NOT-OD-00-039.html.
PUBLIC ACCESS TO RESEARCH DATA THROUGH THE FREEDOM OF INFORMATION ACT: The
Office of Management and Budget (OMB) Circular A-110 has been revised to
provide public access to research data through the Freedom of Information Act
(FOIA) under some circumstances. Data that are (1) first produced in a
project that is supported in whole or in part with Federal funds and (2) cited
publicly and officially by a Federal agency in support of an action that has
the force and effect of law (i.e., a regulation) may be accessed through FOIA.
It is important for applicants to understand the basic scope of this
amendment. NIH has provided guidance at
https://grants.nih.gov/grants/policy/a110/a110_guidance_dec1999.htm.
Applicants may wish to place data collected under this PA in a public archive,
which can provide protections for the data and manage the distribution for an
indefinite period of time. If so, the application should include a
description of the archiving plan in the study design and include information
about this in the budget justification section of the application. In
addition, applicants should think about how to structure informed consent
statements and other human subjects procedures given the potential for wider
use of data collected under this award.
STANDARDS FOR PRIVACY OF INDIVIDUALLY IDENTIFIABLE HEALTH INFORMATION: The
Department of Health and Human Services (DHHS) issued final modification to
the "Standards for Privacy of Individually Identifiable Health Information",
the "Privacy Rule," on August 14, 2002. The Privacy Rule is a federal
regulation under the Health Insurance Portability and Accountability Act
(HIPAA) of 1996 that governs the protection of individually identifiable
health information, and is administered and enforced by the DHHS Office for
Civil Rights (OCR). Those who must comply with the Privacy Rule (classified
under the Rule as "covered entities") must do so by April 14, 2003 (with the
exception of small health plans which have an extra year to comply).
Decisions about applicability and implementation of the Privacy Rule reside
with the researcher and his/her institution. The OCR website
(http://www.hhs.gov/ocr/) provides information on the Privacy Rule, including
a complete Regulation Text and a set of decision tools on "Am I a covered
entity?" Information on the impact of the HIPAA Privacy Rule on NIH processes
involving the review, funding, and progress monitoring of grants, cooperative
agreements, and research contracts can be found at
https://grants.nih.gov/grants/guide/notice-files/NOT-OD-03-025.html.
URLs IN NIH GRANT APPLICATIONS OR APPENDICES: All applications and proposals
for NIH funding must be self-contained within specified page limitations.
Unless otherwise specified in an NIH solicitation, Internet addresses (URLs)
should not be used to provide information necessary to the review because
reviewers are under no obligation to view the Internet sites. Furthermore,
we caution reviewers that their anonymity may be compromised when they
directly access an Internet site.
HEALTHY PEOPLE 2010: The Public Health Service (PHS) is committed to achieving
the health promotion and disease prevention objectives of "Healthy People
2010," a PHS-led national activity for setting priority areas. This PA is
related to one or more of the priority areas. Potential applicants may obtain
a copy of "Healthy People 2010" at http://www.health.gov/healthypeople.
AUTHORITY AND REGULATIONS
This program is described in the Catalogue of Federal Domestic Assistance at
http://www.cfda.gov/ in the following citations: No. 93.855, Immunology,
Allergy, and Transplantation Research and No. 93.856, Microbiology and
Infectious Diseases Research. Awards are made under authorization of Sections
301 and 405 of the Public Health Service Act as amended (42 USC 241 and 284)
and administered under NIH grants policies and Federal Regulations 42 CFR 52
and 45 CFR Parts 74 and 92. This program is not subject to the
intergovernmental review requirements of Executive Order 12372 or Health
Systems Agency review.
The NIH Grants Policy Statement is available at
https://grants.nih.gov/grants/policy/policy.htm. This document includes general
information about the grant application and review process; information on the
terms and conditions that apply to NIH Grants and cooperative agreements; and
a listing of pertinent offices and officials at the NIH. All awards are
subject to the terms and conditions, cost principles, and other considerations
described in the NIH Grants Policy Statement.
The PHS strongly encourages all grant recipients to provide a smoke-free
workplace and discourage the use of all tobacco products. In addition, Public
Law 103-227, the Pro-Children Act of 1994, prohibits smoking in certain
facilities (or in some cases, any portion of a facility) in which regular or
routine education, library, day care, health care, or early childhood
development services are provided to children. This is consistent with the
PHS mission to protect and advance the physical and mental health of the
American people.